Monthly Archives: July 2008

Competitive Technologies signs distribution agreement with Excel Life Sciences

July 31st, 2008|

Competitive Technologies has signed an agreement with Excel Life Sciences granting them exclusive distribution rights in India for the company's pain management therapy device. 

Bristol-Myers Squibb to buy remaining stake in ImClone

July 31st, 2008|

Bristol-Myers Squibb has proposed to acquire the stake in ImClone it does not already own for $60 per share in cash, in a deal valued at about $4.5 billion.

Fast-growing Fake Drugs Market Hits Pharma Units Across the Globe

July 31st, 2008|

Central and State authorities must understand the gravity of the threat the pharmaceuticals industry has been facing from counterfeit drugs and find solutions to the problems and difficulties faced by the regulators…[English]-[French]-[Spanish]

Wockhardt net marginally up by 4% in Q2

July 30th, 2008|

Wockhardt Ltd, a Mumbai based Rs 2650-crore plus pharma company, has failed to generate any significant growth in profitability during the second quarter ended June 2008 mainly due to higher input costs.

Sun, Lupin, Reddy’s get US FDA approval for generic Depakote

July 30th, 2008|

Three Indian companies, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories and Lupin Limited, have received approval from US FDA for the first generic versions of Depakote delayed-release tablets (divalproex sodium). 

Sagent Pharma launches amiodarone HCl injection

July 30th, 2008|

Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced that it has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia – a potentially life-threatening irregular heart beat.

Orchid’s Q1 FY09 income grows 30%

July 30th, 2008|

Chennai-based Generic pharma major, Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) achieved a total income of Rs 306.33 crore for the quarter ended June 30, 2008 (Q1 FY08-09) in comparison to Rs 236.27 crore registered during the corresponding first quarter of last fiscal, growing by 29.6%.

Mylan receives approval for hypertension drug Nisoldipine in US

July 30th, 2008|

Mylan Inc.,   subsidiary  Mylan Pharmaceuticals Inc, has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nisoldipine extended-release (ER) tablets, 20 mg, 30 mg and 40 mg.

Millennium begins phase-1 trial series of MLN4924

July 30th, 2008|

Millennium, The Takeda Oncology Company has initiated of a phase-1 trial series of MLN4924, the company's first-in-class, small molecule inhibitor of the Millennium-discovered target, the Nedd 8 Activating Enzyme (NAE).

Lupin acquires German based Hormosan Pharma

July 30th, 2008|

Lupin Limited, a Rs 2700 crore plus company based in Mumbai, has acquired Hormosan Pharma GmbH (Hormosan), a German sales and marketing generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS). 

Ramadoss identifies Pharma and healthcare Sector for India, Brazil cooperation

July 30th, 2008|

Union Minister for Health and Family Welfare Dr. Anbumani Ramadoss has called for strengthening of cooperation in the field of health between India and Brazil. In his opening statement at the India-Brazil bilateral meeting here today, Dr. Ramadoss emphasized the need for cooperation in the field of research.

Cadila Healthcare consolidated net up by 21%

July 30th, 2008|

Cadila Healthcare has consolidated net profit increased by 21.3 per cent to Rs 89.68 crore from Rs 73.93 crore in the corresponding period of last year, largely due to significant growth in other income. Its net sales increased by 22.3 per cent to Rs 685.71 crore from Rs 560.85 crore.

US FDA seizes Xiadafil VIP tablets of SEI Pharmaceuticals

July 29th, 2008|

US Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Florida.

Unimark Remedies to acquire KDL Biotech for Rs 13.73 cr

July 29th, 2008|

Unimark Remedies Ltd, a Rs 421 crore company engaged in manufacturing of bulk drugs in segment such as cardio vascular and antibiotics, formulations in antibiotics, oncology, etc., is acquiring KDL Biotech Ltd for a total consideration of Rs 13.73 crore.

Thermo Fisher Scientific acquires FIBERLite Centrifuge

July 29th, 2008|

Thermo Fisher Scientific Inc., the global player in serving science, has acquired FIBERLite Centrifuge, Inc., of Santa Clara, California- a supplier of carbon fiber centrifuge rotors, a strong and lightweight alternative.

Teva’s Q2 profit rises above expectations

July 29th, 2008|

Teva Pharmaceutical’s second-quarter profit rose 5 percent to $539 million, or 65 cents per share, compared with $515 million, or 63 cents per share, a year earlier.

Ortho-McNeil-Janssen gets FDA grant for TOPAMAX

July 29th, 2008|

Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, has pediatric exclusivity from the US Food and Drug Administration for TOPAMAX (topiramate)

MorphoSys licenses RapMAT technology to Astellas

July 29th, 2008|

Astellas Pharma Inc. has exercised a pre-existing option to use MorphoSys's proprietary RapMAT technology for faster antibody optimization as part of the existing technology transfer agreements between the two companies.

J B Chemical’s net zooms to Rs 13.64 crore in Q1

July 29th, 2008|

J B Chemicals net profit has taken a quantum jump of 344 per cent to Rs 13.64 crore from Rs 3.07 crore in the similar period of last year.

Glenmark consolidated net up by 102 pc in Q1

July 29th, 2008|

Revenue from the generics business, Glenmark Generics Ltd (GGL) increased by 87.4 per cent to Rs 240.60 crore from Rs 128.38 crore in the corresponding period of last year. The revenues from speciality business, including out licensing revenues, declined marginally by 2.3 per cent to Rs 225.85 crore from Rs 231.05 crore due to the decline in primary sales for the Latin America, Africa, Asia and CIS region. The secondary sales growth in these markets continues to be strong above 40 per cent as per third party data sources.